SecBot SecBot
6-K ·Filed Aug 18, 2026

HCM

HUTCHMED (China) Ltd
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001648257-26-000051
Notable filing: 6-K
Actionable Insight • Neutral

No trading action warranted. This is a purely administrative AIM Rule 17 disclosure with zero financial or operational impact on HUTCHMED. Monitor for any future filings that might indicate a broader governance concern, but none is present here.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.64
T+0 close · Aug 18, 2026 · via day close
Latest settled
+19.30%
T+60 · $15.08
Vs SPY
+20.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $12.64entry
  2. T+1 · 3mo ago −0.40%α −0.61% · $12.59
  3. T+5 · 3mo ago −3.01%α −2.81% · $12.26
  4. T+20 · 2mo ago +6.49%α +8.23% · $13.46
  5. T+60 · 6d ago +19.30%α +20.30% · $15.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED filed a routine 6-K disclosing that its Chairman, Dr. Dan Eldar, was formerly a director of S.D. Sight Diagnostics Ltd., which entered insolvency proceedings in Israel. The filing explicitly states the insolvency does not involve HUTCHMED or its operations, and the amount involved (~$1M) is immaterial relative to HUTCHMED's $2.1B market cap. This is a purely administrative AIM Rule disclosure with no financial or operational impact on the company.

Key Facts

  • Chairman Dr. Dan Eldar was a director of S.D. Sight Diagnostics from Dec 2018 to Mar 2026.
  • S.D. Sight entered insolvency proceedings in Israel; a trustee was appointed on May 28, 2026.
  • The amount involved is approximately NIS 3,057,876 (~US$1,019,292).
  • Neither S.D. Sight nor Hutchison Water Israel E.P.C Ltd (which holds ~9.98% of S.D. Sight) is part of HUTCHMED.
  • The Board states the proceedings have no impact on HUTCHMED's businesses or operations.

Financial Impact

Immaterial, ~$1M insolvency proceeding involving an unrelated third party, less than 0.05% of HUTCHMED's market cap.

Risk Factors

  • Reputational risk from association of a director with an insolvent entity, though the company has explicitly disclaimed any operational link.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001648257-26-000051
Document: hcm-20260818xex99d1.htm0001648257-26-000051
Document: 0001648257-26-000051-index-headers.html0001648257-26-000051
Document: 0001648257-26-000051-index.html0001648257-26-000051
Document: 0001648257-26-000051.txt0001648257-26-000051

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 18, 2026